Mikanisal (Ketoconazole)

Ketoconazole blocks the fungal enzyme lanosterol 14α‑demethylase, which is essential for synthesising ergosterol, a key component of the fungal cell membrane. Inhibiting this step disrupts membrane integrity, leading to leakage of cellular contents and ultimately fungal cell death. This targeted action reduces the fungal load on the skin.

The specific dose and frequency of Mikanisal are determined by the prescribing healthcare professional based on the infection type, severity, and patient characteristics. Typically, a thin layer is applied to the affected area once or twice daily for the period recommended by the clinician.

Safety data for topical ketoconazole in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against any possible risks. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician before starting treatment.

To request Mikanisal, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mikanisal (ketoconazole) belongs to the imidazole class, offering broad‑spectrum activity against dermatophytes and yeasts. Compared with allylamine agents such as terbinafine, ketoconazole may be less potent against certain dermatophytes but is effective for seborrheic dermatitis and pityriasis versicolor. Choice of therapy depends on infection type, resistance patterns, and clinician preference.

Mikanisal should be stored at room temperature, ideally below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat, and direct sunlight. Do not freeze the preparation, and ensure the container is tightly closed when not in use.

Apply a thin, even layer of Mikanisal to clean, dry skin over the affected area. Gently rub it in until fully absorbed. Follow the prescribing clinician’s instructions regarding frequency (usually once or twice daily) and duration of therapy, and avoid covering the treated skin with occlusive dressings unless directed.

While most reactions are mild, serious risks include severe allergic responses such as angioedema, urticaria, or Stevens‑Johnson syndrome. Rare systemic effects may occur if significant absorption happens, especially with extensive use. Patients should stop the product and seek immediate medical attention if they notice blistering, widespread rash, or signs of an allergic reaction.

Mikanisal is contraindicated in individuals with a known hypersensitivity to ketoconazole, other imidazole antifungals, or any component of the formulation. It should also be avoided on severely damaged, inflamed, or broken skin, and in patients who have experienced severe cutaneous reactions to topical antifungals in the past.